Evidence map›Paper›PMID 38665823›Full record

ArticleRSC medicinal chemistry2024

Luísa Carvalho, Fábio Pedroso de Lima, Mónica Cerqueira, Ana Silva, Olívia Pontes, Sofia Oliveira-Pinto, Sara Guerreiro, Marta D Costa, Sara Granja, Patrícia Maciel and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Luísa CarvalhoLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Fábio Pedroso de LimaDepartment of Chemistry, University of Minho Campus of Gualtar Braga Portugal fproenca@quimica.uminho.pt.
Mónica CerqueiraLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Ana SilvaLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Olívia PontesLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Sofia Oliveira-PintoLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Sara GuerreiroLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.ORCID https://orcid.org/0000-0001-7521-5119
Marta D CostaLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.ORCID https://orcid.org/0000-0002-6247-0548
Sara GranjaLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Patrícia MacielLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.ORCID https://orcid.org/0000-0002-0920-6350
Adhemar Longatto-FilhoLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.
Fátima BaltazarLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.ORCID https://orcid.org/0000-0002-1770-4544
Fernanda ProençaDepartment of Chemistry, University of Minho Campus of Gualtar Braga Portugal fproenca@quimica.uminho.pt.
Marta CostaLife and Health Sciences Research Institute (ICVS), University of Minho Campus of Gualtar Braga Portugal martafcosta@med.uminho.pt.ORCID https://orcid.org/0000-0002-4287-0659
University of Minho · PTPolytechnic Institute of Porto · PTUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and the limited therapeutic options show poor efficacy in patients, associated to severe side effects and development of resistance. Considering that chromene-based scaffolds proved to be attractive candidates for cancer therapy, herein we prepared new chromeno[2,3-

Identifiers

PMID38665823
PMCPMC11042168
OpenAlexW4392956922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.